Citi maintains buy rating for Incyte stock amid promising trial data

Citi analysts reaffirmed their Buy rating on Incyte (INCY) with an $88 price target following positive proof-of-concept data for its mCALR inhibitor, INCA33989, in essential thrombocythemia (ET) patients, showing a 79% overall response rate and reductions in mutant CALR variant allele frequency (VAF) in 88% of patients. The company also received FDA approval for Zynyz for advanced squamous cell carcinoma of the anal canal. However, BMO Capital maintains an Underperform rating due to concerns over future growth, while UBS remains Neutral, citing safety concerns and uncertainty around Incyte's drug development pipeline.

Analysis

Citi analysts have reiterated a Buy rating for Incyte (NASDAQ: INCY) with an $88.00 price target, buoyed by promising proof-of-concept data for its mCALR inhibitor, INCA33989. In a Phase 1 trial involving 41 high-risk, treatment-resistant essential thrombocythemia (ET) patients, INCA33989 demonstrated a 79% best overall response rate, with 88% of patients showing reductions in mutant CALR variant allele frequency over a median exposure of 20 weeks. While 81% of participants experienced adverse events, these were predominantly mild, and no dose reductions or dose-limiting toxicities were reported. This clinical progress is supported by Incyte's robust financial health, characterized by more cash than debt and a current ratio of 2.04. Further positive news includes the FDA approval of Zynyz, a PD-1 inhibitor, for advanced squamous cell carcinoma of the anal canal. However, sentiment is not universally positive; BMO Capital maintains an Underperform rating, citing concerns about future growth strategies and a projected delay in the mCALR antibody launch until at least 2028. Similarly, UBS holds a Neutral rating, expressing caution over safety and the advancement of pipeline candidates like povorcitinib and mCALR to registrational studies. The stock currently trades at $67.23, within an analyst target range of $52 to $96, and is considered slightly undervalued by InvestingPro's Fair Value analysis.

Key Decisions for Investors

• Investors should carefully weigh the positive clinical trial results for INCA33989 and the recent FDA approval for Zynyz against the cautious outlooks from BMO Capital and UBS, particularly concerning long-term growth and pipeline execution risks.
• Monitor upcoming data releases, especially from the myelofibrosis cohorts of the INCA33989 trial, as these could significantly influence market perception and valuation given Incyte's existing presence with Jakafi.
• Evaluate Incyte's current valuation, noted as slightly undervalued by InvestingPro, in the context of its strong balance sheet, but remain aware of potential development timelines and safety considerations highlighted by some analysts.